Revvity PE Ratio 2010-2025 | RVTY
Current and historical p/e ratio for Revvity (RVTY) from 2010 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Revvity PE ratio as of June 09, 2025 is 18.84.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Revvity PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-06-09 | 92.88 | 39.52 | |
| 2025-03-31 | 105.72 | $2.35 | 44.99 |
| 2024-12-31 | 111.46 | $2.21 | 50.43 |
| 2024-09-30 | 127.51 | $2.07 | 61.60 |
| 2024-06-30 | 104.59 | $1.38 | 75.79 |
| 2024-03-31 | 104.66 | $1.21 | 86.50 |
| 2023-12-31 | 108.88 | $5.50 | 19.80 |
| 2023-09-30 | 110.19 | $5.95 | 18.52 |
| 2023-06-30 | 118.18 | $6.54 | 18.07 |
| 2023-03-31 | 132.51 | $7.68 | 17.25 |
| 2022-12-31 | 139.35 | $4.58 | 30.43 |
| 2022-09-30 | 119.52 | $4.90 | 24.39 |
| 2022-06-30 | 141.19 | $5.34 | 26.44 |
| 2022-03-31 | 173.13 | $6.11 | 28.33 |
| 2021-12-31 | 199.44 | $8.08 | 24.68 |
| 2021-09-30 | 171.83 | $10.05 | 17.10 |
| 2021-06-30 | 153.04 | $10.51 | 14.56 |
| 2021-03-31 | 127.08 | $9.55 | 13.31 |
| 2020-12-31 | 142.08 | $6.48 | 21.93 |
| 2020-09-30 | 124.20 | $3.68 | 33.75 |
| 2020-06-30 | 97.00 | $2.63 | 36.88 |
| 2020-03-31 | 74.38 | $2.02 | 36.82 |
| 2019-12-31 | 95.87 | $2.04 | 47.00 |
| 2019-09-30 | 84.02 | $2.10 | 40.01 |
| 2019-06-30 | 94.97 | $2.27 | 41.84 |
| 2019-03-31 | 94.92 | $2.22 | 42.76 |
| 2018-12-31 | 77.31 | $2.13 | 36.30 |
| 2018-09-30 | 95.66 | $1.12 | 85.41 |
| 2018-06-30 | 71.96 | $1.25 | 57.56 |
| 2018-03-31 | 74.33 | $2.52 | 29.50 |
| 2017-12-31 | 71.72 | $2.64 | 27.17 |
| 2017-09-30 | 67.58 | $3.60 | 18.77 |
| 2017-06-30 | 66.70 | $3.31 | 20.15 |
| 2017-03-31 | 56.76 | $2.05 | 27.69 |
| 2016-12-31 | 50.92 | $2.13 | 23.90 |
| 2016-09-30 | 54.71 | $2.15 | 25.45 |
| 2016-06-30 | 51.05 | $2.10 | 24.31 |
| 2016-03-31 | 48.10 | $1.95 | 24.67 |
| 2015-12-31 | 52.02 | $1.88 | 27.67 |
| 2015-09-30 | 44.57 | $1.54 | 28.94 |
| 2015-06-30 | 50.97 | $1.43 | 35.65 |
| 2015-03-31 | 49.45 | $1.44 | 34.34 |
| 2014-12-31 | 42.22 | $1.38 | 30.59 |
| 2014-09-30 | 42.02 | $1.68 | 25.01 |
| 2014-06-30 | 45.08 | $1.67 | 26.99 |
| 2014-03-31 | 43.30 | $1.48 | 29.25 |
| 2013-12-31 | 39.55 | $1.46 | 27.09 |
| 2013-09-30 | 36.14 | $0.75 | 48.19 |
| 2013-06-30 | 31.05 | $0.65 | 47.77 |
| 2013-03-31 | 32.08 | $0.69 | 46.49 |
| 2012-12-31 | 30.20 | $0.61 | 49.51 |
| 2012-09-30 | 27.98 | $0.00 | 0.00 |
| 2012-06-30 | 24.42 | $0.05 | 488.47 |
| 2012-03-31 | 26.12 | $0.01 | 2611.58 |
| 2011-12-31 | 18.83 | $0.01 | 1882.53 |
| 2011-09-30 | 18.02 | $3.22 | 5.59 |
| 2011-06-30 | 25.17 | $3.02 | 8.33 |
| 2011-03-31 | 24.51 | $3.26 | 7.52 |
| 2010-12-31 | 24.02 | $3.27 | 7.35 |
| 2010-09-30 | 21.46 | $1.15 | 18.66 |
| 2010-06-30 | 19.10 | $1.16 | 16.47 |
| 2010-03-31 | 22.02 | $0.85 | 25.91 |
| 2009-12-31 | 18.91 | $0.73 | 25.90 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $10.948B | $2.755B |
| Revvity Inc. provides products, services and solutions to the diagnostics, life sciences and applied services markets worldwide. Its operating segment includes Discovery & Analytical Solutions and Diagnostics. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection and imaging technologies. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection and imaging technologies. Revvity Inc., formerly known as PerkinElmer Inc., is based in Waltham, Massachusetts. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $142.561B | 26.74 |
| Elevance Health (ELV) | United States | $88.026B | 11.36 |
| CVS Health (CVS) | United States | $80.784B | 10.04 |
| Cencora (COR) | United States | $55.036B | 19.15 |
| DiDi Global (DIDIY) | China | $23.580B | 35.79 |
| Natera (NTRA) | United States | $22.420B | 0.00 |
| BioMerieux (BMXMF) | France | $16.097B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $13.007B | 0.00 |
| Solventum (SOLV) | United States | $12.962B | 13.72 |
| CochLear (CHEOY) | Australia | $11.342B | 0.00 |
| ICON (ICLR) | Ireland | $11.283B | 10.49 |
| Doximity (DOCS) | United States | $10.905B | 50.49 |
| Viatris (VTRS) | United States | $10.340B | 3.55 |
| HealthEquity (HQY) | United States | $9.613B | 42.11 |
| Avantor (AVTR) | United States | $9.165B | 13.32 |
| Medpace Holdings (MEDP) | United States | $8.574B | 22.77 |
| Sonic Healthcare (SKHHY) | Australia | $8.388B | 0.00 |
| Charles River Laboratories (CRL) | United States | $7.243B | 14.19 |
| Amplifon S.p.A (AMFPF) | Italy | $5.378B | 29.44 |
| Bausch + Lomb (BLCO) | Canada | $4.238B | 24.96 |
| BrightSpring Health Services (BTSG) | United States | $4.157B | 38.48 |
| Sotera Health (SHC) | United States | $3.508B | 19.93 |
| Surgery Partners (SGRY) | United States | $2.994B | 38.93 |
| Alignment Healthcare (ALHC) | United States | $2.924B | 0.00 |
| Concentras Parent (CON) | United States | $2.830B | 16.36 |
| Organon (OGN) | United States | $2.537B | 2.70 |
| GeneDx Holdings (WGS) | United States | $2.066B | 79.58 |
| Ardent Health Partners (ARDT) | United States | $1.957B | 8.34 |
| Premier (PINC) | United States | $1.900B | 14.43 |
| Progyny (PGNY) | United States | $1.883B | 41.45 |
| PACS (PACS) | United States | $1.586B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.468B | 29.36 |
| Teladoc Health (TDOC) | United States | $1.298B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.214B | 9.24 |
| Establishment Labs Holdings (ESTA) | $1.113B | 0.00 | |
| CareDx (CDNA) | United States | $1.098B | 17.15 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.011B | 0.00 |
| Agilon Health (AGL) | United States | $0.944B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.818B | 7.66 |
| QDM (QDMI) | Hong Kong, SAR China | $0.752B | 0.00 |
| Nutex Health (NUTX) | United States | $0.654B | 9.90 |
| Embecta (EMBC) | United States | $0.579B | 3.90 |
| LifeMD (LFMD) | United States | $0.566B | 0.00 |
| Enhabit (EHAB) | United States | $0.546B | 44.92 |
| InnovAge Holding (INNV) | United States | $0.520B | 0.00 |
| SBC Medicals (SBC) | United States | $0.507B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.472B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.471B | 10.60 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.437B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.244B | 0.00 |
| Oncology Institute (TOI) | United States | $0.232B | 0.00 |
| Beauty Health (SKIN) | United States | $0.202B | 0.00 |
| DocGo (DCGO) | United States | $0.163B | 26.67 |
| KindlyMD (KDLY) | United States | $0.150B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.099B | 0.00 |
| So-Young (SY) | China | $0.091B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.081B | 0.00 |
| KindlyMD (NAKA) | United States | $0.081B | 0.00 |
| OncoCyte (OCX) | United States | $0.080B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.063B | 0.00 |
| NeueHealth (NEUE) | United States | $0.060B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.058B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.057B | 0.00 |
| ModivCare (MODV) | United States | $0.050B | 0.00 |
| Biodesix (BDSX) | United States | $0.042B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.029B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.013B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.012B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.010B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.006B | 0.00 | |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| INVO Fertility (IVF) | United States | $0.003B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |